Sermorelin
A 29-amino-acid GHRH analog formerly FDA-approved for childhood growth hormone deficiency.
In plain English
Sermorelin is a synthetic version of the first 29 amino acids of growth-hormone-releasing hormone (GHRH). It stimulates the pituitary to release the body's own growth hormone in a pulsatile pattern. Sermorelin was FDA-approved in the 1990s as Geref for diagnosing and treating childhood growth-hormone deficiency, but the originator product was withdrawn from the market in 2008 — not for safety reasons, but for commercial ones. Today it is used primarily as a compounded prescription product in anti-aging and longevity clinics. People commonly research sermorelin for sleep quality, recovery, body composition, and the symptoms of age-related GH decline.
What it is
Sermorelin acetate is a synthetic peptide corresponding to the biologically active first 29 amino acids of human GHRH (1-44).
Mechanism (summary)
Sermorelin binds the GHRH receptor on pituitary somatotrophs, stimulating endogenous growth hormone release. Because it works through the pituitary's own regulatory feedback, it preserves the pulsatile pattern of GH secretion.
Why people research it
- Childhood growth-hormone deficiency (historical FDA indication)
- Age-related decline in GH/IGF-1
- Sleep architecture (slow-wave sleep)
- Body composition and recovery
Human evidence
Older trials demonstrated efficacy in pediatric GH deficiency for height velocity. Smaller adult studies show increases in IGF-1 and modest body-composition changes; large modern RCTs for anti-aging endpoints are lacking.
Animal / lab evidence
Animal data support GH release and downstream IGF-1 effects with intact pituitary function.
Key studies
Each summary explains the design, what was found, and what it doesn't prove.
A review arguing that GHRH peptides like sermorelin are a more natural way to raise GH than injecting GH directly.
Older adults on the sermorelin sequence had higher IGF-1 and small body-composition improvements after months of treatment.
History
Approved as Geref in 1990 for pediatric GHD. Withdrawn from the market in 2008 for commercial reasons. Compounded sermorelin remains widely used in age-management medicine.
PeptidePedia is for educational and informational purposes only. We do not sell peptides, prescribe peptides, provide medical advice, or recommend treatment. Peptides may not be approved for human use except in specific legal prescription or clinical contexts. Always consult a licensed medical professional before making health decisions.
Related peptides
A long-acting GHRH analog studied as a research peptide for sustained growth hormone elevation.
A selective ghrelin receptor agonist studied as a growth hormone secretagogue with minimal effects on cortisol or prolactin.
A long-acting GHRH analog FDA-approved as Egrifta for HIV-associated visceral fat accumulation.